Opdivo from BMS Wins Another US Approval

24.05.2016 - The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s (BMS) cancer drug, Opdivo, to treat classical Hodgkin Lymphoma (HL). The approval is the eighth for...